Prognosis and staging of non-alcoholic fatty liver disease

BMJ (Online)

Volumn 343, Issue 7836, 2011, Pages 1236-

  Jepsen, Peter ^a   Grønbæk, Henning ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

CARDIOVASCULAR DISEASE; EDITORIAL; FATTY LIVER; HUMAN; LIVER BIOPSY; METABOLIC SYNDROME X; MORTALITY; NONALCOHOLIC FATTY LIVER; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

FATTY LIVER; FEMALE; HUMANS; MALE;

EID: 83755178800     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d7302     Document Type: Editorial

References (7)

1. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341-50.
2. Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010;51:595-602.
3. Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E, et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011;343:d6891.
4. Andersen PK, Liestøl K. Attenuation caused by infrequently updated covariates in survival analysis. Biostatistics 2003;4:633-49.
5. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274-85.
6. Choi SS, Diehl AM. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Curr Opin Lipidol 2008;19:295-300. (Pubitemid 351653569)
7. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2011;33:525-40.